Please login to the form below

Not currently logged in
Email:
Password:

New Molecular Entities

This page shows the latest New Molecular Entities news and features for those working in and with pharma, biotech and healthcare.

Daiichi starts challenging Astellas for Japanese AML market

drugs. If everything goes according to plan, Vanflyta will be the first of seven new molecular entities to emerge from’s Daiichi oncology pipeline between now and 2025.

Latest news

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    We will be sharing some of our latest research at the 2019 AACR Annual Meeting, including 28 new molecular entities and six combinations.". ... Baselga also confirmed that it will "highlight an exciting new phase of scientific discovery", in the form of

  • EMA sees approval numbers rise in 2018 EMA sees approval numbers rise in 2018

    The figures nevertheless show the EMA is still lagging significantly behind the FDA, the US drug regulator reaching a record-breaking tally of 59 new molecular entities for the year. ... Lastly, the EMA’s key human medicines committee, the CHMP, has a

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    The final tally for novel drug approved at the US regulator last year stands at 59 new molecular entities as of 27 December – smashing all previous records. ... The FDA approved 46 drugs in 2017, which had itself matched a 2015 record, but last year

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    Barron made much of GSK’s immunology and immuno-oncology portfolio on the company’s interim results call, saying it has 27 new molecular entities (NMEs) in these areas which account ... Meanwhile, vaccines grew 12% to £1.92bn led by new shingles

  • GSK: we won’t be splitting up any time soon GSK: we won’t be splitting up any time soon

    The company has 27 immunomodulatory new molecular entities (NME) in clinical trials, around 60% of its total clinical pipeline. ... Also announced was a major new alliance with consumer gene testing company 23andMe.

More from news
Approximately 2 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    In one fell swoop three new giant specialists will emerge: Novartis claims the cancer crown; GSK vaccines; Lilly Animal Health. ... Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    Despite the new schemes, healthcare in China is still considered expensive, with out-ofpocket payments commonly high. ... Conversely, however, Brazil's uptake of New Molecular Entities (NMEs) between 2006-2010 was the highest of the BRIC nations – with

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Chancellor Merkel has proposed a new system of financial regulation within the EU. ... Source: EFPIA, 2009. According to Vfa in 2010 only 26 new molecular entities were launched in the German market, compared to 36 in 2009.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics